← Back to Company DatabaseVisit Website
GRAIL
Multi-cancer early detection through blood tests.
AcquiredMenlo Park, CAFounded 2016
About
GRAIL is a healthcare company focused on early cancer detection. Its flagship Galleri test uses next-generation sequencing and machine learning to detect over 50 types of cancer from a single blood draw. The company was spun out of Illumina and later acquired by the genomics giant.
Total Funding
$5.0BKey Product
Galleri multi-cancer early detection testGeography
North AmericaKey Investors
IlluminaARCH Venture PartnersJeff Bezos
Focus Areas
Early Detection / ScreeningDiagnosticsAI / Machine Learning
Technology
Liquid BiopsyGenomics / SequencingAI / Machine Learning
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026